申请人:Hoechst Aktiengesellschaft
公开号:US05461043A1
公开(公告)日:1995-10-24
Enterally absorbable diastereomers of 1-(isopropoxycarbonyloxy)ethyl (6R,7R)-7-[2-(2-aminothiazol-4-yl)-2-(Z)-(methoxyimino)acetamido]-3-(metho xymethyl)-3-cephem-4-carboxylate of the formula I ##STR1## and their physiologically acceptable salts and also diastereomerically pure salts of the compounds of the formula II ##STR2## where HX is a mono- or polybasic acid and where X is an inorganic or organic physiologically acceptable anion, and a process for the preparation of these compounds of the formula I or II, which comprises first precipitating the more sparingly soluble diastereomer of the formula IV in the mixing together of 1 equivalent of a solution of the diastereomer mixture of the formula III with 0.2-2 equivalents of a solution of the acid component HY and separating it off by filtration, then precipitating the more readily soluble diastereomer of the formula IV from the filtration solution, it being possible for the acid component HY to be identical or different in the consecutive partial steps and any desired sequence of addition of different acid components HY being possible, and optionally further purifying the obtained salts by crystallization, are described.
化合物I的可进入体内的对映异构体是1-(异丙氧羰氧基)乙基(6R,7R)-7- [2-(2-氨基噻唑-4-基)-2-(Z)-(甲氧亚胺)乙酰氨基] -3-(甲氧甲基)-3-头孢烯-4-羧酸酯,其化学式为I,以及它们的生理上可接受的盐,还包括化合物II的对映异构体纯盐,其中HX是一种单基或多基酸,X是一种生理上可接受的无机或有机阴离子,以及制备这些化合物I或II的过程,其中包括首先在将式III的对映异构体混合物的溶液与酸组分HY的0.2-2当量的溶液混合物中沉淀出较不溶的式IV的对映异构体,并通过过滤将其分离,然后从过滤溶液中沉淀出较易溶的式IV的对映异构体,酸组分HY可以在连续的部分步骤中相同或不同,并且可以按任意顺序添加不同的酸组分HY,并且可以通过结晶进一步纯化所得盐。